Kornimate/medical-research-clean huggingface dataset:
preoperative pain control in liver surgery patients

Conditions: Pain, Postoperative; Hepatocellular Carcinoma

Summary: pregabalin 150mg or placebo are administered 1 hour preoperatively in patients undergoing partial hepatectomy. postoperatively, patients receive morphine as rescue analgesic. morphine consumption in the first 48 hours is documented. postoperative pain is measured by the visual analogue scale (vas) score.

methods: in this randomized controlled trial, patients undergoing partial hepatectomy will be administered a single pre-operative dose of pregabalin or a placebo. primary endpoints are as follows: * post-operative analgesic requirements * post-operative vas scale (rated 0-10) * complications * post-operative antiemetic requirement * length of stay

Eligibility criteria:
inclusion criteria: * patients undergoing partial hepatectomy exclusion criteria: * contraindication against pregabalin * creatinine \> 2.0 mg/dl * ggt \>165, ast \>105, alt \>135 * peptic ulcus * haemorrhagic diathesis * angina pectoris, myocardial infarction * stroke * bronchial asthma * opioid abuse

Keywords: hepatocellular carcinoma hepatectomy randomized controlled trials(rcts) postoperative pain
telitacicept and low-dose steroids in refractory myasthenia gravis

Conditions: Myasthenia Gravis; Autoimmune Diseases

Summary: this study is designed to explore the efficacy and safety of telitacicept combined with low-dose steroids for the treatment of refractory mg, and to investigate related biomarkers such as immunoglobulins, blys/april, and achr-ab titers, in order to clarify whether telitacicept can rapidly and effectively help achieve mg treatment goals and assist in steroid reduction.


Eligibility criteria:
inclusion criteria: * age between 18-85 years, both genders included； * meet the diagnostic criteria of the 2020 chinese mg guidelines, with positive serological testing for achr-ab; * clinical classification of type i to type iva according to the mgfa; * meet the criteria for refractory mg in the 2022 japanese mg guidelines: poor response to standard treatment, intolerance to standard treatment drugs due to adverse reactions, frequent relapses/exacerbations after reduction of standard treatment drugs, frequent need for rescue treatment due to disease fluctuations, frequent myasthenic crises, and comorbidities that limit the use of standard treatment; * patients with unstable symptoms (mg-adl score ≥6 or qmg ≥8) despite treatment with standard therapeutic regimens before enrollment, defined as follows: 1. patients on monotherapy with corticosteroids: a corticosteroid dose ≤60mg/d, and a stable dose for at least 1 month before enrollment; 2. patients on combination therapy with corticosteroids and other immunosuppressants: a corticosteroid dose ≤60mg/d, and a stable dose for at least 1 month before enrollment, while other immunosuppressants such as azathioprine, methotrexate, tacrolimus, and mycophenolate mofetil have been stable for 6 months prior to the study start and will remain stable during the study period; * patients must provide written informed consent. exclusion criteria: * patients with active infections, such as herpes zoster, hiv, active pulmonary tuberculosis, or active hepatitis; * patients with thymic tumors or those who have undergone thymectomy within the past 6 months; * patients with coexisting malignant tumors; * patients with severe hepatic or renal insufficiency; * patients who have received intravenous immunoglobulin or undergone plasmapheresis within the last 2 months; * patients who have received any live vaccines within the last 3 months or plan to receive any vaccines during the study period; * women who are currently pregnant or breastfeeding, and patients who plan to conceive during the trial period; * patients with allergies to human-derived biological products; * patients who have participated in any clinical trial within the last 28 days or within 5 half-lives of the study medication (whichever is longer); * any other patients deemed unsuitable for enrollment by the investigator (e.g., severe psychiatric disorders).
the clinical study of shr-9839 for injection in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: this study is an open-label, phase i clinical trial of shr-9839 in patients with advanced solid tumors. the whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.


Eligibility criteria:
inclusion criteria: 1. patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment, or standard treatment is not applicable currently; 2. have at least one measurable tumor lesion per recist v1.1; 3. ecog performance status of 0-1; 4. life expectancy ≥ 12 weeks; 5. adequate bone marrow and organ function; 6. subjects must voluntarily agree to participate in the trial and sign a written informed consent form. exclusion criteria: 1. patients with active central nervous system metastases or meningeal metastases; 2. received anti-tumor treatment such as chemotherapy, biotherapy, targeted therapy, immunotherapy, radical radiotherapy, or other unlisted clinical research drugs or treatments within 4 weeks prior to the first use of the study drug; 3. history of serious cardiovascular and cerebrovascular diseases; 4. subjects who received\>30gy of radiation therapy within 4 weeks before the first medication, and those who received ≤ 30gy of palliative radiation therapy within 7 days before the first medication; 5. adverse reactions of previous anti-tumor treatment have not recovered to grade ≤ 1 per nci-ctcae v5.0.
the effect of aspirin on angiogenesis proteins in women on tamoxifen therapy

Conditions: Breast Cancer; Angiogenesis

Summary: changes in major angiogenic proteins have been seen following initiation of tamoxifen and aromatase inhibitor therapy in women with breast cancer. one source of these proteins is the circulating platelet pool. the investigators hypothesize that in addition to their anti-platelet properties, agents such as aspirin can be used as targeted anti-angiogenesis therapy. the investigators will determine the influence of aspirin on the release of angiogenic proteins from platelets in 35 patients with breast cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven breast cancer * pre or post-menopausal * age \>18 * completed adjuvant non-hormonal therapy \>30 days prior to initiation of study (surgery and/or chemotherapy and/or radiation therapy) * platelet count and hemoglobin within normal ranges for local lab within 30 days of initiation of study therapy * receiving tamoxifen therapy for at least 90 days prior to initiation of study therapy, and is expected to continue that therapy for the duration of the study (75 days) exclusion criteria: * chemotherapy, radiation therapy or surgery within 30 days of study therapy * current use of aspirin, anti-platelet or anti-coagulation agents on a continuous basis * prior history of gastrointestinal or central nervous system bleeding, or documented or self-reported blood in stools or bright red blood per rectum

Keywords: breast cancer angiogenesis aspirin tamoxifen
vespar: comparing vessel-sparing anastomotic repair and transecting anastomotic repair in isolated short bulbar strictures.

Conditions: Urethral Stricture; Surgery; Urologic Diseases

Summary: the investigators want to verify whether the surgical outcome of vessel-sparing anastomotic repair in isolated short bulbar urethral strictures is not inferior to the surgical outcome of transecting anastomotic repair. furthermore, the investigators compare the functional outcome of both techniques verifying if there is less erectile dysfunction after vessel-sparing anastomotic repair than after transecting anastomotic repair.

a randomized controlled trial comparing vessel-sparing anastomotic repair (vsar) and transecting anastomotic repair (tar) in isolated short bulbar urethral strictures (maximum 3 centimeter) for both surgical and functional outcome, to demonstrate that vsar is not inferior to tar regarding the surgical outcome, and to demonstrate a benefit for vsar over tar regarding postoperative erectile function.

Eligibility criteria:
inclusion criteria: * voluntary signed written informed consent (according to the rules of good clinical practice and national regulations) * male * age \>= 18 years * fit for operation, based on the surgeon's expert opinion * isolated short (=\< 3cm) bulbar urethral stricture confirmed by preoperative retrograde urethrography (rug), voiding cysto-urethrography (vcug), cystoscopy, ultrasonography or a combination of investigations * unique urethral stricture * urethral stricture =\< 3 cm * urethral stricture at the bulbar segment * patient declares that it will be possible for him to attend the follow-up consultation exclusion criteria: * absence of signed written informed consent * age \<18 years * female patients * transgender patients * patients unfit for operation * concomitant urethral strictures at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck) * urethral strictures exceeding 3 cm * a unique urethral stricture at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck) * lichen sclerosus related strictures * strictures after failed hypospadias repair * patients with neurogenic bladder * shift of technique to augmented urethroplasty due to any circumstance * history of pelvic radiation therapy * active treatment to enhance erectile function (such as pde5-inhibitors and intracavernous injections) at the moment of prescreening for inclusion in this trial * any condition or situation, which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study * patient declares that it will be impossible for him to attend the follow-up consultations

Keywords: urethral stricture urethroplasty bulbar urethra reconstructive surgery lower urinary tract symptoms erectile function
the predictive value of clinical and immunological factors in the development of pneumonia after traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: the development of pneumonia and other infections is one of the most common complications of a traumatic brain injury (tbi). prior studies have also found that patients suffering from tbi also develop immune dysfunction consistent with an immunosuppressed state shortly after the traumatic event. specifically, it has been shown that patients with a tbi have impaired delayed type hypersensitivity (dth), cellular immunity and humoral immunity. the humoral arm of the immune system is particularly involved in defending the host against extracellular bacteria and is primarily composed of b-cells, immunoglobulins and complement. surgery and trauma impair the clonal expansion of antibody producing b lymphocytes causing hypogammaglobulinemia, through a mechanism involving t lymphocytes. in addition, during the systemic inflammatory process, pro-inflammatory cytokines such as tumor necrosis factor alpha (tnf-alpha), interleukin 1 (il-1beta) and interleukin 6 (il-6) are released. nuclear factor kappa beta (nf-kb) is a transcriptional regulatory protein that is involved in the expression of proinflammatory cytokines and appears to act at a critical step in the transcription of many proinflammatory genes. the hypothesis of this study is that the hypogammaglobulinemia from the immune dysfunction and the induction of nf-kb from the inflammatory process are, in part, responsible for the development of pneumonia and other infectious complications identified after tbi. this study has two specific aims: the primary specific aim of this study is to determine the association between serum immunoglobulin or nf-kb levels and the development of pneumonia in patients suffering from traumatic brain injury (tbi). the secondary specific aim of this study is to determine the relative contribution of clinical variables such as apache ii-iii score and injury severity score as compared to immunological variables (serum immunoglobulins and nf-kb) to the development of pneumonia in patients suffering from tbi.


Eligibility criteria:
inclusion criteria: * \> 18 yrs * admitted to icu in capital health region with a tbi and \> 1 of the following: * an initial resuscitated (sys bp\>90 mmhg and o2 sat \>90%) gsc of ≤ 8 * a post resuscitation (sys bp\>90 mmhg and o2 sat \>90%) gcs at presentation to the hospital of ≤ 8 in the absence of sedation * a post resuscitation (sys bp\>90 mmhg and o2 sat \>90%) gcs within 72 hrs of hospital admission of ≤ 8 in the absence of sedation * intracranial pressure monitoring * decompressive craniectomy * presence of subfalcine, uncal, or supratentorial herniation either clinically or radiologically exclusion criteria: * longer than 5 days since ictus of tbi

Keywords: traumatic brain injury
validity and reliability of the turkish version of the pectus carinatum evaluation questionnaire for patients with pectus carinatum

Conditions: Pectus Carinatum; Compliance; Brace

Summary: based on the hypothesis that the chest wall was still pliable in adolescence and could be reshaped in a normal position with the external suppressor applied on the chest, a pressure orthosis was started to be used in the pectus carinatum. it is the focus of attention as it is an alternative method to surgery for patients. however, the patient's compliance with the orthosis is difficult. therefore, in our study, we aimed to investigate the turkish validity and reliability of the pectus carinatum evaluation questionnaire, which is a questionnaire investigating the compliance with orthosis treatment in patients diagnosed with pectus carinatum by the doctor.


Eligibility criteria:
inclusion criteria: 1. patients who have been diagnosed with pectus carinatum by a doctor, have an orthosis indication (2 cm above the protrusion level) and who are given the orthosis for the first time 2. having a correction pressure below 10 pounds per square inch (psi) in the compression test 3. between the ages of 10-18, 4. having dissatisfaction with this defect exclusion criteria: 1. having severe scoliosis (cobb angle over 20 degrees) 2. having chronic systemic disease 3. having a serious psychiatric illness 4. having complex mixed type pectus deformity
comparing kidscore™ d5 and idascore®. the kida study

Conditions: IVF; Infertility

Summary: a pilot study to gather information on clinical pregnancy rates for preparation of the planning of a larger randomized controlled trial comparing two decision support tools: the deep learning tool idascore® and the current annotation model, kidscore™ d5.


Eligibility criteria:
inclusion criteria: 1. patients undergoing ivf/icsi-treatment with controlled ovarian stimulation with gonadotrophins and the intention to treat by transfer of a single day 5 fresh blastocyst on day 5. 2. at least two good quality blastocysts (gqb) on day 5 (3bb or better on the gardner scale), originating from normally fertilized oocytes (2pn). exclusion criteria: 1. previous participation in this rct 2. concurrent participation in another investigation 3. intention to perform any form of preimplantation genetic testing 4. fertility preservation 5. planned transfer on day 2-4 6. female age \>42 years 7. a reduced likelihood of obtaining two good quality blastocysts on day 5 as evidenced by an afc \<5 (if available, afc=antral follicle count)

Keywords: embryos embryo scoring blastocyst selection pregnancy rate live birth rate
near patient molecular testing in sepsis

Conditions: Sepsis; Systemic Inflammatory Response Syndrome

Summary: the purpose of the study is to evaluate the real-time performance of a new host response test (septicyte rapid) for differentiating sepsis from non-infection/systemic inflammatory response syndrome among patients suspected of sepsis within the first 24 hours of intensive care unit (icu) admission.

the ability of septicyte rapid to differentiate sepsis from infection-negative systemic inflammation will be determined using retrospective physician diagnosis performed by an external panel of three physicians not involved with the care of the patients.

Eligibility criteria:
inclusion criteria: 1. ≥18 years old on the date of icu admission 2. systemic inflammatory response syndrome (sirs) present, as defined by the presence of two or more of the following: 1. temperature \> 38°c or \< 36°c 2. heart rate \> 90 beat/min 3. tachypnea \> 20/min or paco2 \< 32 mmhg 4. wbc count \> 12 000/mm3 or \ 10% immature neutrophils (bands) 3. consent to study inclusion, either by patient or legal surrogate before study-related sample processing 4. study sample collection within 24 hours of icu admission order exclusion criteria: 1. age less than 18 years old on the day of icu admission 2. no order to admit to icu 3. not physically admitted to icu 4. commencement of non-prophylactic antibiotics ≥ 24 hours prior to icu admission 5. study sample collection \> 24 hours from icu admission order 6. no clinical cultures or serologic tests obtained when sepsis was suspected 7. elective cardiac surgery patients with an expected duration in icu of less than 24 hours 8. transfer from another icu where subject was admitted for ≥ 24 hours.
depressive symptoms in acute manic episode

Conditions: Bipolar Disorder

Summary: observational, non-interventional, transversal, multicenter, open label (no treatment is involved). the primary objective is to detect the prevalence of depressive symptoms in bipolar patients admitted to a psychiatric unit due to an acute mania episode. secondary objectives include 1) to evaluate, the relationship between depressive symptoms and severity of mania; 2) to evaluate, the relationship between depressive symptoms and anxiety; 3) to evaluate, the relationship between depressive symptoms and psychotic symptoms; 4) to evaluate, the relationship between depressive symptoms and insight; 5) to evaluate, the relationship between depressive symptoms and clinical global impression; 6) to evaluate, the relationship between depressive symptoms and previous treatment with antipsychotics (whatever the antipsychotic was); 7) to evaluate, the relationship between depressive symptoms and length of admission; 8) to evaluate factors (demographic, evolution...) which could be involved in the presence of depressive symptoms within an acute manic episode; 9) to evaluate, the difference on the initial prescription due to the detection of depressive symptoms; 10) to evaluate, if exists, differences on the previous psychiatric diagnosis in patients with and without depressive symptoms. the primary endpoint is score of the madrs (montgomery-asberg depression rating scale) in bipolar patients with acute mania


Eligibility criteria:
inclusion criteria: * diagnosed of bipolar disorder based on dsm-iv-tr * patients admitted to an acute inpatient psychiatric unit due to an acute manic episode (as defined in dsm-iv_tr) * provision of written informed consent. * total score in young mania rating scale \>=20 * able to understand and comply with the requirements of the study exclusion criteria: * mental retardation * patients with manic symptoms are due to substance use, based in the investigator opinion * patients with unstable organic diseases, who are not receiving adequate treatment, according the investigator opinion. * participation in a trial with drugs within 4 weeks of enrolment into this study.

Keywords: acute mania bipolar disorder depressive symptoms mixed mania
study of laparoendoscopic single site hysterectomy in benign and preinvasive uterine disease

Conditions: Benign or Preinvasive Uterine Disease

Summary: to compare the efficacy between single-port and three-port laparoscopic assisted vaginal hysterectomy in patients with benign or preinvasive uterine disease

this study intended to conduct a randomized trial to determine whether less lavh has a faster recovery rate than three-port lavh.

Eligibility criteria:
inclusion criteria: * patient who undergo laparoscopic assisted vaginal hysterectomy due to following gynecologic disease 1. uterine leiomyoma 2. uterine adenomyosis 3. endometrial hyperplasia 4. cervical intraepithelial neoplasia including carcinoma in situ 5. dysfunctional uterine bleeding 6. other benign gynecologic disease requiring hysterectomy * american society of anesthesiologists physical status classification i-ii * patient who have signed an written informed consent exclusion criteria: * uncontrolled medical disease * active infectious disease * previous pelvic radiation therapy * patient who requiring further procedure excluding hysterectomy, unilateral or bilateral salpingooophorectomy / salpingectomy / oophorectomy * patient who undergoes subtotal hysterectomy * patient who have other pain source excluding gynecologic disease * pregnancy and lactating woman

Keywords: less benign uterine disease lavh
effectiveness of nephrochecktm test to predict acute kidney injury following advanced cardiac replacement therapies

Conditions: Acute Kidney Injury; Heart Failure

Summary: the purpose of this study is to test how well the nephrochecktm test, a noninvasive laboratory test performed on urine, predicts loss of kidney function in patients that have had a heart transplant or a left ventricular assist device (lvad) or total artificial heart (tah) implanted.

current strategies for aki detection rely primarily on elevations in serum creatinine in conjunction with diminished urine output. unfortunately, deviations in these crude parameters of renal function are largely insensitive and late manifestations of aki, where acute tubular necrosis has likely already transpired and therefore well beyond the phase where preventive measures may be instituted. early phase biomarkers, insulin-like growth factor-binding protein 7 ("igfbp7") and tissue inhibitor of metalloproteinases-2 ("timp-2") are critical mediators of g1 cell cycle arrest of renal tubular cells during the early phase of cellular injury, providing a potential therapeutic window to prevent permanent damage. to date, no study has evaluated the efficacy of these early phase renal biomarkers for detecting aki in advanced heart failure patients undergoing cardiac replacement therapies. therefore, the aim of this prospective observational study will be to evaluate the effectiveness of the nephrochecktm to predict aki in patients undergoing transplant, lvad implant, or tah implant.

Eligibility criteria:
inclusion criteria: * patients who will receive lvad or heart transplantation exclusion criteria: * patients who are unable to give consent

Keywords: left ventricular assist device heart transplantation perioperative acute kidney injury renal kidney total artificial heart